Psychiatry

Respondents in trigger states had significantly greater increased anxiety and depression symptoms following the Dobbs abortion decision on June 24, 2022 than respondents in non-trigger states.

A new study found individuals aged 18 – 55 with treatment-resistant schizophrenia had significantly greater adverse events than individuals aged ≥ 55 years.

A new study found individuals with OCD had an 82% increased risk of all-cause mortality as well as an increased risk of mortality due to natural causes and unnatural causes.

In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.

The first Lungcast of 2024 touches on one of the most pressing issues in medicine: burnout, with an organizational expert.

For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.

A new study found, after bariatric surgery, participants had a 9.5% reduction in anxiety and a 22.3% reduction in depression.

A new study does not support the home-use tDCS since the findings show the home-use tDCS combined with either a digital psychological intervention or digital placebo was not superior to the sham.

In an interview, Hassan Dashti, PhD, RD, discusses the main takeaway of a study on anorexia nervosa being associated with the morning chronotype.

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

A new study found individuals with anorexia nervosa were associated with having a morning chronotype and vice versa.

Mindfulness-Oriented Recovery Enhancement plus methadone treatment is a promising treatment option for patients with opioid use disorder, having been significantly associated with less return to drug use and methadone treatment dropout, a new study found.

Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.

A nationwide Taiwan-based study found benzodiazepine use during pregnancy was linked to roughly a 70% increased risk of miscarriage.

After participants with autism wore biosensors tracking physiological signals, a logistic regression predicted aggressive behaviors 3 minutes before it happened.

In a new study, children had 8 - 40% higher odds of a psychiatric condition if their parents scored 1 SD above the mean on the general psychopathology. This demonstrates how parents with psychiatric disorders have a higher likelihood of passing it down to their children.

Miller discusses the EMERGENT-2 trial and the benefits of xanomeline-trospium for treating adults with schizophrenia, for which the treatment is currently awaiting FDA decision.

Jennifer Mitchell, PhD, discusses MAPS Public Benefit Corporations’ recent New Drug Application submission for MDMA-Assisted Therapy for PTSD and what the treatment’s potential approval could mean for people with PTSD.

The FDA approved zuranolone for postpartum depression in August, and the drug recently hit the market for patients this month. Experts are celebrating its delivery of care and rapid response rate.

Tight glycemic target treatment compares similarly to less-tight glycemic target treatment in terms of how it affects the mental health status of women with gestational diabetes mellitus.

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.

A phase 2b clinical trial met its primary endpoint with positive topline results, showing MM-120 (lysergide d-tartrate) can reduce symptoms of generalized anxiety disorder, reflected in the Hamilton Anxiety rating scale scores.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

In recent conversations with experts in epilepsy, the impact of stigmatization remains high for patients and ongoing efforts by clinicians to address this issue in the clinical setting has been underscored, despite the global lack of awareness about new treatments and other resources.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.